
Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC
The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).
The FDA has accepted for priority review the supplemental Biologics License Application for pembrolizumab (Keytruda), Merck’s programmed death-1 (PD-1) inhibitor antibody. The application, which includes phase 3 data from the KEYNOTE-024 study, seeks approval for using pembrolizumab as first-line treatment in patients diagnosed with programmed death ligand-1 (PD-L1)—expressing advanced non-small cell lung cancer (NSCLC).
Back in June, the
“Chemotherapy has been the foundation of first-line treatment for non-small cell lung cancer for decades, so the significant improvement in survival in patients with high PD-L1 expression seen with Keytruda compared to chemotherapy is welcome news,” said Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories. “We appreciate the opportunity to work with regulatory authorities to make Keytruda a first-line treatment option in non-small cell lung cancer,” he added.
Today’s announcement comes a week after Roche
The field of immuno-oncology is witnessing stiff competition among the top 3 drug developers: Bristol-Myers Squibb (BMS), Merck, and Roche. While nivolumab (Opdivo) has been the market leader thus far, BMS
Currently, pembrolizumab is approved for treatment of patients with unresectable or metastatic melanoma, patients with PD-L1—expressing NSCLC who have progressed on platinum-based chemotherapy, and patients with advanced head and neck squamous cell carcinoma who have progressed on platinum-based chemotherapy.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.